TG Therapeutics (NASDAQ:TGTX) reported quarterly earnings of $0.05 per share which missed the analyst consensus estimate of $0.33 by 84.85 percent. This is a 70.59 percent decrease over earnings of $0.17 per share from the same period last year. The company reported quarterly sales of $240.335 million which beat the analyst consensus estimate of $229.721 million by 4.62 percent. This is a 70.27 percent increase over sales of $141.148 million the same period last year.